+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Endometriosis

  • ID: 4421388
  • Report
  • 37 pages
  • Datamonitor Healthcare
1 of 3

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bayer
  • Daewon
  • Hope Medicine
  • Neurocrine Biosciences
  • MORE
This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:
  • The author estimates that in 2017, there were 188.7 million prevalent cases of endometriosis in women aged 15–49 years worldwide, and forecasts that number to increase to 199.1 million prevalent cases by 2026.
  • Endometriosis affects an estimated one in 10 women in the reproductive age group of 15–49 years. The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available.
  • Half of the industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III. Therapies in mid-to-late-stage development for endometriosis focus on targets such as the gonadotropin-releasing hormone receptor, progesterone receptor, luteinizing hormone receptor, androgen receptors, and follicle-stimulating hormone. The majority of pipeline drugs in mid-to-late-stage development for endometriosis are administered via the oral route, with only one product being tested as a topical formulation.
  • High-impact upcoming events in the endometriosis space comprise topline Phase III results for two trials of Relugolix. The overall likelihood of approval of a Phase I gynecology asset is 13.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 11.0 years from Phase I to approval, compared to 12.7 years in the overall obstetrics/gynecology space.
  • There have been 13 licensing and asset acquisition deals involving endometriosis drugs during 2014–19. The largest deal was in 2017, when AstraZeneca obtained commercialization rights to Zoladex in the US and Canada from TerSera Therapeutics for $320m.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for endometriosis have been in the early and mid-phases of development, with 74% of trials in Phase I–II, and only 26% in Phase III–IV.
  • The US has a substantial lead in the number of endometriosis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the endometriosis space is dominated by completed trials. Bayer has the highest number of completed clinical trials for endometriosis, with 37 trials.
  • Bayer leads industry sponsors with the highest number of clinical trials for endometriosis, followed by Takeda.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bayer
  • Daewon
  • Hope Medicine
  • Neurocrine Biosciences
  • MORE
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • Surgery
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Proellex (Oral) for Endometriosis (June 25, 2019)
  • Linzagolix for Endometriosis (June 18, 2018)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • AbbVie And Neurocrine Biosciences' Elagolix For Endometriosis
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Bayer, Hope Medicine Strike Hair Loss Antibody License
  • Daewon Licenses Tium’s Novel Endometriosis Therapeutic
PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of endometriosis, 2017–26
Figure 2: Overview of pipeline drugs for endometriosis in the US
Figure 3: Pipeline drugs for endometriosis, by company
Figure 4: Pipeline drugs for endometriosis, by drug type
Figure 5: Pipeline drugs for endometriosis, by classification
Figure 6: Linzagolix for Endometriosis (June 18, 2018): Phase IIb - EDELWEISS
Figure 7: Key upcoming events in endometriosis
Figure 8: Probability of success in the endometriosis pipeline
Figure 9: Licensing and asset acquisition deals in endometriosis, 2014–19
Figure 10: Parent patents in endometriosis
Figure 11: Clinical trials in endometriosis
Figure 12: Top 10 drugs for clinical trials in endometriosis
Figure 13: Top 10 companies for clinical trials in endometriosis
Figure 14: Trial locations in endometriosis
Figure 15: Endometriosis trials status
Figure 16: Endometriosis trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of endometriosis, 2017–26
Table 2: Marketed drugs for endometriosis
Table 3: Pipeline drugs for endometriosis in the US
Table 4: Proellex (Oral) for Endometriosis (June 25, 2019)
Table 5: Linzagolix for Endometriosis (June 18, 2018)
Table 6: Historical global sales, by drug ($m), 2014–18
Table 7: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie
  • AstraZeneca
  • Bayer
  • Daewon
  • Hope Medicine
  • Neurocrine Biosciences
  • Takeda
  • TerSera Therapeutics
  • Tium
Note: Product cover images may vary from those shown
Adroll
adroll